Skip to main content
SpringerLink
Log in

Recently Approved Pharmacologic Agents to Improve Outcomes in Heart Failure

  • Chapter
  • First Online:
Cardiovascular Hemodynamics

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 1800 Accesses

Abstract

Traditional pharmacologic approaches to the management of patients with heart failure with reduced systolic function (HFrEF) have been based on neurohormonal inhibition on a background of hemodynamic effects. The agents that have been shown to be associated with improved outcomes in this patient population are inhibitors of the renin-angiotensin-aldosterone (RAAS) system, mineralocorticoids, and beta-blockers. More recently, two agents were FDA-approved for improved outcomes in HFrEF, sacubitril/valsartan, and ivabradine. Sacubitril/valsartan combines RAAS inhibition (valsartan) with inhibition of natriuretic peptide breakdown, while ivabradine is a novel means of heart rate control. While the evidence for clinical benefit of sacubitril/valsartan is substantial, evidence for the use of ivabradine is emerging.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314:1547–52.

    Article  CAS  Google Scholar 

  2. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl Med. 1987;316:1429–35.

    Article  Google Scholar 

  3. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.

    Article  Google Scholar 

  4. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–10.

    Article  CAS  Google Scholar 

  5. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.

    Article  CAS  Google Scholar 

  6. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.

    Article  CAS  Google Scholar 

  7. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001–7.

    Article  Google Scholar 

  8. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–17.

    Article  CAS  Google Scholar 

  9. Kagawa CM, Sturtevant FM, Van Arman CG. Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone. J Pharm Exp Ther. 1959;126:123–30.

    CAS  Google Scholar 

  10. Zannad F, McMurray JJ, Frum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.

    Article  CAS  Google Scholar 

  11. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.

    Article  Google Scholar 

  12. Srikanth Y, Aronow WS, Mondal P, Chabbott DR. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Arch Med Sci. 2017;13:1207–16.

    Google Scholar 

  13. Cohn JN, Tognoni G, for the Valsartan Trial Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675.

    Google Scholar 

  14. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32–43.

    Article  Google Scholar 

  15. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–6.

    Article  CAS  Google Scholar 

  16. Braunwald E. The path to an angiotensin receptor neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65:1029–41.

    Article  CAS  Google Scholar 

  17. Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66.

    Article  CAS  Google Scholar 

  18. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95.

    Article  CAS  Google Scholar 

  19. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110:2618–26.

    Article  CAS  Google Scholar 

  20. Chandra A, Lewis EF, Claggett BL, et al. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2018;3:498–505. https://doi.org/10.1001/jamacardio.2018.0398 . Published online April 4.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Desai AS, Vardeny O, Claggett B, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2017;2:79–85.

    Article  Google Scholar 

  22. Bernardez-Pereira S, Ramires FJA, de Melo RFT, Pereira-Barretto AC. Was the enalapril dose too low in the PARADIGM-HF trial? Cardiol Rev. 2018; https://doi.org/10.1097/CRD.0000000000000193. [Epub ahead of print]

  23. Langenickel TH, Tsubouchi C, Ayalasomayajula S, et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid-ß concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol. 2016;81:878–90.

    Article  CAS  Google Scholar 

  24. Solomon SD, Rizkala AR, Gong J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF Trial. JACC Heart Fail. 2017;5:471–82.

    Article  Google Scholar 

  25. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared to enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61.

    Article  CAS  Google Scholar 

  26. Ayalasomayajula S, Langenickel T, Pal P, et al. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor neprilysin inhibitor. Clin Pharmacokinet. 2017;56:1461–78.

    Article  CAS  Google Scholar 

  27. Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction. The prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail. 2016;9:e002744.

    Article  CAS  Google Scholar 

  28. Sulfi S, Timmis AD. Ivabradine – the first selective sinus node I f channel inhibitor in the treatment of stable angina pectoris. Int J Clin Pract. 2006;60:222–8.

    Article  CAS  Google Scholar 

  29. Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol. 2003;42:688–96.

    Article  CAS  Google Scholar 

  30. Joannides R, Moore N, Iacob M, et al. Comparative effects of ivabradine, a selective heart rate lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61:127–37.

    Article  CAS  Google Scholar 

  31. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, and I f inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–23.

    Article  Google Scholar 

  32. Tendera M, Chassany O, Ferrari R, et al. Quality of life with ivabradine in patients with angina pectoris. The study assessing the morbidity and mortality benefits of the I f inhibitor ivabradine in patients with stable coronary artery disease quality of life substudy. Circ Cardiovasc Qual Outcomes. 2016;9:31–8.

    Article  Google Scholar 

  33. Tardif JC, Ponikowski P, Kahan T, et al. Efficacy of the I f current inhibitor ivabradine in patients with chronic stable angina receiving beta blocker therapy: a 4-month, randomize, placebo-controlled trial. Eur Heart J. 2009;30:540–8.

    Article  CAS  Google Scholar 

  34. European Medicines Agency. Ivabradine: European public assessment report – scientific discussion. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000597/WC500043587.pdf

  35. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.

    Article  CAS  Google Scholar 

  36. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337–45.

    Article  CAS  Google Scholar 

  37. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–9.

    Article  Google Scholar 

  38. Swedberg K, Komaida M, Bohm M, Borer JS, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet. 2010;376:875–85.

    Article  CAS  Google Scholar 

  39. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32:2395–404.

    Article  Google Scholar 

  40. Tardif JC, O’Meara E, Komajda M, SHIFT Investigators, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507–15.

    Article  CAS  Google Scholar 

  41. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11–22.

    Article  Google Scholar 

  42. Narayanan MA, Reddy YNV, Baskaran J, et al. Ivabradine in the treatment of systolic heart failure – a systematic review and meta-analysis. World J Cardiol. 2017;9:182–90.

    Article  Google Scholar 

  43. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776–803.

    Article  Google Scholar 

  44. Yancy CW, Januzzi JL, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;71:201–30.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Gill Heart and Vascular Institute, University of Kentucky Medical Center, Lexington, KY, USA

    David C. Booth

  2. Heart Failure/Cardiac Transplant Program, The Gill Heart and Vascular Institute, Lexington, KY, USA

    Navin Rajagopalan

Authors
  1. David C. Booth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Navin Rajagopalan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David C. Booth .

Editor information

Editors and Affiliations

  1. Premier Health Advocates, Beachwood, OH, USA

    Arman T. Askari

  2. Gill Heart and Vascular Institute, University of Kentucky HealthCare, Lexington, KY, USA

    Adrian W. Messerli

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Booth, D.C., Rajagopalan, N. (2019). Recently Approved Pharmacologic Agents to Improve Outcomes in Heart Failure. In: Askari, A., Messerli, A. (eds) Cardiovascular Hemodynamics. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-030-19131-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-19131-3_8

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-19130-6

  • Online ISBN: 978-3-030-19131-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation